Article thumbnail

Tumor growth suppression in C57BL/6J mice bearing LLC tumors treated with hPK5/NGR-hPK5 and cisplatin.

By Weiwei Jiang (323409), Guanghui Jin (323410), Dingyuan Ma (323411), Feng Wang (44414), Tong Fu (323413), Xiao Chen (260187), Xiwen Chen (323415), Kunzhi Jia (323418), Faiz M. M. T. Marikar (323420) and Zichun Hua (206669)


<p>When the tumor size reached about 50 mm<sup>3</sup>, the mice were injected i.p. every other day with hPK5/NGR-hPK5 (on days 0, 2, 4, 6, 8 and 10; 6 times totally) and 24 h after each treatment mice were injected i.p. with cisplatin (on days 1, 3, 5, 7, 9 and 11; 6 times totally). The dose of hPK5 or NGR-hPK5 was 1.25 mg/kg/day in all protein therapy groups. Control mice were treated with injections of PBS. <b><i>A</i></b><b>,</b> hPK5 combined with 2 mg/kg/day of cisplatin; <b><i>B</i></b><b>,</b> NGR-hPK5 combined with 2 mg/kg/day of cisplatin; <b><i>C</i></b><b>,</b> hPK5 combined with 0.5 mg/kg/day of cisplatin; <b><i>D</i></b><b>,</b> NGR-hPK5 combined with 0.5 mg/kg/day of cisplatin. Tumor volume was calculated by the formula (L×W<sup>2</sup>×0.52). Eight to ten LLC tumor-bearing mice were used in each sample unit, and the data shown were the mean volume ± SE. * <i>p</i><0.05.</p

Topics: Molecular Biology, Cancer, suppression, mice, bearing, llc, tumors, treated
Year: 2013
DOI identifier: 10.1371/journal.pone.0037132.g007
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.